Zombie biotech Eleven Bio sheds staff in the final wind down
Hammered by back-to-back pivotal trial failures, Eleven Biotherapeutics ($EBIO) is continuing to wind down its operations. The biotech noted that it whacked 14 staffers last week, according to a notice filed with the SEC on Wednesday.
By its own account, there’s a skeleton staff of 4 still in place, with less and less on the table. The ophthalmology-focused company did not respond to a request for comment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.